Optimized subcutaneous administration of BHV-1300 achieved rapid, deep and sustained lowering of IgG, differentiating Biohaven's (BHVN) new small molecule class of degraders from the monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback